Brisbane Clinical Trials
The Biosimilar Study BRIS
The purpose of this study is to investigate a potential new treatment for rheumatoid arthritis (RA).
2 x 5 nights
19 visits
This is a biosimilar study to demonstrate the similarities between the study drug and the reference medications Actemra® and RoActemra®. These current medications are used to treat rheumatoid arthritis (RA) – a chronic inflammatory disorder affecting many joints causing severe pain. These medications work by slowing the progression of the disease which then reduces joint damage and inflammation.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!
Eligibility
Biological Sex Healthy Males or Females of non-childbearing potential (i.e. surgically sterile or post-menopausal)
Age 18 – 50 years old, inclusive
BMI 18.5-30kg/m²
Body Weight 50 to 100kg
Medical History No significant medical history and no tattoos on the outer upper arms
Medications Not taking any medication
Smoking History Non-smokers